MIRA Pharmaceuticals' topical Ketamir-2 shows successful drug release in IVRT study

MIRA PHARMACEUTICALS, INC.

Topical Ketamir-2 demonstrated dose-proportional release in in vitro release testing, enabling non-opioid pain therapy.
Preclinical efficacy studies in inflammatory and neuropathic pain models to begin shortly.
Company evaluating Fast Track designation with FDA; U.S. topical pain relief market projected >$11.5B in 2025.
Oral Ketamir-2 in Phase 1 trial; Phase 2a for diabetic neuropathy expected later in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.